NASDAQ:PRNB Principia Biopharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Principia Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $100.27 +0.22 (+0.22 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$99.95Now: $100.27▼$100.3950-Day Range$83.49MA: $95.54▼$101.0752-Week Range$25.35Now: $100.27▼$101.89Volume1.97 million shsAverage Volume726,449 shsMarket Capitalization$3.33 billionP/E RatioN/ADividend YieldN/ABeta0.86 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.2 Analyst's Opinion Consensus RatingPrincipia Biopharma has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $97.00, Principia Biopharma has a forecasted downside of 3.3% from its current price of $100.27.Amount of Analyst CoveragePrincipia Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesPrincipia Biopharma has received 100 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPrincipia Biopharma has received 100 “underperform” votes. (Add your “underperform” vote.)Community SentimentPrincipia Biopharma has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Principia Biopharma and other stocks. Vote “Outperform” if you believe PRNB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRNB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPrincipia Biopharma does not currently pay a dividend.Dividend GrowthPrincipia Biopharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Principia Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,355,885.00 in company stock.Percentage Held by InsidersOnly 16.01% of the stock of Principia Biopharma is held by insiders.Percentage Held by Institutions95.54% of the stock of Principia Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Principia Biopharma are expected to decrease in the coming year, from ($2.79) to ($4.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Principia Biopharma is -41.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Principia Biopharma is -41.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrincipia Biopharma has a P/B Ratio of 9.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.14 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRNB Previous Symbol CUSIPN/A CIKN/A Webwww.principiabio.com Phone650-416-7700Debt Debt-to-Equity RatioN/A Current Ratio17.01 Quick Ratio17.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.16 million Price / Sales94.71 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book9.16Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-53,790,000.00 Net MarginsN/A Return on Equity-23.08% Return on Assets-21.11%Miscellaneous Employees65 Outstanding Shares33,209,000Market Cap$3.33 billion Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $100.27 +0.22 (+0.22 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PRNB News and Ratings via Email Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter. Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions How has Principia Biopharma's stock price been impacted by Coronavirus (COVID-19)? Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRNB stock has increased by 86.1% and is now trading at $100.27. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Principia Biopharma? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Principia Biopharma. When is Principia Biopharma's next earnings date? Principia Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Principia Biopharma. How were Principia Biopharma's earnings last quarter? Principia Biopharma Inc (NASDAQ:PRNB) issued its quarterly earnings data on Thursday, August, 6th. The company reported $0.31 earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.03) by $1.34. The firm earned $50 million during the quarter, compared to analyst estimates of $50 million. View Principia Biopharma's earnings history. What price target have analysts set for PRNB? 7 brokers have issued 12 month price targets for Principia Biopharma's stock. Their forecasts range from $82.00 to $100.00. On average, they anticipate Principia Biopharma's stock price to reach $97.00 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts' price targets for Principia Biopharma. Are investors shorting Principia Biopharma? Principia Biopharma saw a drop in short interest in August. As of August 31st, there was short interest totaling 2,000,000 shares, a drop of 25.9% from the August 15th total of 2,700,000 shares. Based on an average trading volume of 1,400,000 shares, the short-interest ratio is presently 1.4 days. View Principia Biopharma's Short Interest. Who are some of Principia Biopharma's key competitors? Some companies that are related to Principia Biopharma include Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), CureVac B.V. (CVAC), GALAPAGOS NV/S (GLPG), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Myokardia (MYOK), Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). View all competitors. What other stocks do shareholders of Principia Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU), QUALCOMM (QCOM), Crispr Therapeutics (CRSP), Taiwan Semiconductor Mfg. (TSM) and Activision Blizzard (ATVI). Who are Principia Biopharma's key executives? Principia Biopharma's management team includes the following people: Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)Mr. Martin Babler, CEO & Director (Age 54)Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)Dr. David M. Goldstein, Chief Scientific Officer (Age 53) When did Principia Biopharma IPO? (PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. What is Principia Biopharma's stock symbol? Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB." Who are Principia Biopharma's major shareholders? Principia Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.92%), Cormorant Asset Management LP (4.79%), BVF Inc. IL (4.47%), Vanguard Group Inc. (3.77%), Avidity Partners Management LP (1.65%) and Goldman Sachs Group Inc. (1.13%). Company insiders that own Principia Biopharma stock include Alan Colowick, Christopher Y Chai, Daniel J Becker, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Orbimed Advisors Llc, Plc Glaxosmithkline, Roy C Hardiman, Simeon George and Stefani Wolff. View institutional ownership trends for Principia Biopharma. Which major investors are selling Principia Biopharma stock? PRNB stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Driehaus Capital Management LLC, BVF Inc. IL, Artal Group S.A., EAM Investors LLC, First Trust Advisors LP, Alps Advisors Inc., and AQR Capital Management LLC. Company insiders that have sold Principia Biopharma company stock in the last year include Alan Colowick, Christopher Y Chai, David Goldstein, David M Goldstein, Dolca Thomas, Martin Babler, Roy C Hardiman, and Stefani Wolff. View insider buying and selling activity for Principia Biopharma. Which major investors are buying Principia Biopharma stock? PRNB stock was bought by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Goldman Sachs Group Inc., Logos Global Management LP, Man Group plc, Vanguard Group Inc., Nuveen Asset Management LLC, Tekla Capital Management LLC, and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Plc Glaxosmithkline, and Simeon George. View insider buying and selling activity for Principia Biopharma. How do I buy shares of Principia Biopharma? Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Principia Biopharma's stock price today? One share of PRNB stock can currently be purchased for approximately $100.27. How big of a company is Principia Biopharma? Principia Biopharma has a market capitalization of $3.33 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe. What is Principia Biopharma's official website? The official website for Principia Biopharma is www.principiabio.com. How can I contact Principia Biopharma? Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
